【摘要】 目的研究常规方法联合络酸梭菌活菌片对肝硬化患者的血浆胆碱酯酶、白蛋白(ALB)水平的影响。方法选取本院消化科2016年10月至2018年2月的236位肝硬化患者为研究对象,将符合纳入标准的患者随机分为2组:试验组与对照组。对照组接受本院的肝硬化标准治疗方法;试验组患者在一般的对症治疗基础上给予络酸梭菌活菌片,每次口服2 g,每天3次,持续0. 5个月。用全自动生化分析仪测定2组的血浆胆碱酯酶、ALB水平。结果治疗后,对照组和试验组的胆碱酯酶水平分别为(2. 87±1. 82),(7. 94±2. 45) U·L-1;这2组的ALB水平分别为(34. 02±3. 26),(47. 63±4. 05) g·L-1,组间比较差异均有统计学意义(均P <0. 05)。结论口服络酸梭菌活菌片可以显著提高肝硬化患者血浆胆碱酯酶、ALB水平。更多还原

【Abstract】 Objective To investigate the effect of Clostridium butyricum tablets combined with conventional therapy on the cholinesterase levels and albumin( ALB) levels in patients with liver cirrhosis. Methods The 236 patients with liver cirrhosis from October 2016 to February 2018 in the Department of Gastroenterology of our hospital were selected as the study subjects. The patients were divided into the treatment group and the control group. The patients in the treatment group were given 2 g Clostridium butyricum tablets orally,on the basis of general symptomatic treatment,3 times per day for two weeks; the patients in the control group were stan-dard treatment. The plasma cholinesterase,ALB levels were determined by automatic analyzer. Results The cholinesterase levels in the control group and the treatment group were( 2. 87 ± 1. 82),( 7. 94 ± 2. 45) U·L-1,respectively; the ALB levels in the 2 groups were( 34. 02 ± 3. 26),( 47. 63 ± 4. 05) g·L-1,respectively; comparison between the two groups,the difference was significant( all P < 0. 05).Conclusion Clostridium butyricum tablets can significantly increase plasma cholinesterase and ALB levels in patients with liver cirrhosis.更多还原